The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Dose escalation of the anti-CD47 TTI-622 in NHL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, provides an overview of data from the ongoing, multicenter Phase Ia/Ib dose-escalation and expansion trial (NCT03530683) of TTI-622, an anti-CD47 therapy, in patients with advanced relapsed/refractory non-Hodgkin lymphoma (NHL). Preliminary safety and pharmacokinetic data suggests encouraging activity and low rates of toxicity in patients, and further research in the trial will elucidate the optimal dosing regimen. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
